MIRION TECHNOLOGIES

MIR LISTED NYSE

Fiscal Quarter Ended September 30, 2021 Earnings Presentation

November 12, 2021

Disclaimer

MIRION TECHNOLOGIES

Forward Looking Statements

This presentation and the accompanying oral commentary contain contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate”, “expect”, “hope”, “intend”, “may”, “might”, “should”, “would”, “will”, “understand” and similar words are intended to identify forward looking statements. These forward-looking statements include but are not limited to, statements regarding our future growth prospects, our future financial and operating performance, including our financial outlook for calendar year 2021 and the twelve months ending June 30, 2022, our growth strategy and pending and future acquisitions. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including changes in domestic and foreign business, market, financial, political and legal conditions; risks related to global economic weakness and uncertainty; risks related to the continued growth of Mirion’s end markets; Mirion’s ability to meet or anticipate technology changes; Mirion’s ability to predict its future operational results; risks related to the disruption of Mirion’s customers’ orders or Mirion’s customers’ markets; less favorable contractual terms with large customers; risks related to governmental contracts; Mirion’s ability to mitigate risks associated with long-term fixed price contracts; Mirion’s ability to manage its supply chain or difficulties with third-party manufacturers; risks related to competition; Mirion’s ability to manage disruptions of, or changes in, its independent sales representatives, distributors and original equipment manufacturers; Mirion’s ability to issue debt, equity, or equity-linked securities in the future; Mirion’s ability to realize sales expected from its backlog of orders and contracts; risks related to future legislation and regulation of Mirion’s markets both in the United States and abroad; risks related to the costs or liabilities associated with product liability; Mirion’s ability to source, close and integrate acquisitions, including risks in realizing the value of goodwill and intangible assets and in realizing the expected benefit from any synergies from acquisitions or internal restructuring and improvement efforts; risks related to the global scope of Mirion’s operations, including operations in international and emerging markets; risks related to Mirion’s exposure to fluctuations in foreign currency exchange rates; Mirion’s ability to comply with various laws and regulations and the costs associated with legal compliance; risks related to the outcome of any litigation, government and regulatory proceedings, investigations and inquiries; risks related to Mirion’s ability to protect or enforce its proprietary rights on which its business depends or third-party intellectual property infringement claims; liabilities associated with environmental, health and safety matters; risks associated with Mirion’s limited history of operating as an independent company; Mirion’s ability to attract, train and retain key members of its leadership team and other qualified personnel; Mirion’s ability to effectively manage its growth and recruit and retain key employees; and the impact of the global COVID-19 pandemic on Mirion’s results of operations, financial performance or other financial metrics, or on any of the foregoing risks. Further information on risks, uncertainties and other factors that could affect our financial results are included in the filings we make with the Securities and Exchange Commission (the “SEC”) from time to time, including the prospectus dated November 4, 2021 as part of a registration statement on Form S-1 filed with SEC and any supplements thereto and our periodic reports on Forms 10-K and 10-Q filed or to be filed with the SEC.

You should not rely on these forward-looking statements, as actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of such risks and uncertainties. All forward-looking statements in this press release are based on information available to us as of the date hereof, and we do not assume any obligation to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

Non-GAAP Financial Measures

In addition to our results determined in accordance with U.S. GAAP, we believe non-GAAP measures are useful in evaluating our operating performance, including Adjusted Revenue and Adjusted EBITDA. We use this non-GAAP financial information to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. See the footnotes on the slides where these measures are discussed and the Non-GAAP reconciliations in the Appendix for a description of these non-GAAP financial measures and reconciliations to the most directly comparable GAAP financial measures. Additionally, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations that have not yet occurred, are out of Mirion’s control or cannot be reasonably predicted.

Message from Larry Kingsley

WELL POSITIONED

Great Position in Good Industries

- **A global leader in ionizing radiation detection and measurement technologies**
- History of **innovation, market outgrowth** and successful **M&A**
- **Large, attractive and diverse TAM** with multiple paths to expand
  - Increasing exposure to the **secularly**
  - **growing medical sector**
  - De-risked exposure to the **ultra-long cycle nuclear power sector**
  - Multiple direct adjacencies
- **High incremental margins and asset-lite business model**
- **High barriers to entry**
- **Strong product leadership and brand equity**
- **Diverse and durable customer relationships**
- **Best-in-class management team with long tenured founder CEO in Tom Logan**

UPSIDE POTENTIAL

Significant Upside in Growth and Margins

- **Solid short and long-term organic growth outlook**
  - Attractive underlying market growth
  - Targeting 1-2% market outgrowth
  - Multiple short and medium-term tailwinds
- **Attractive acquisition landscape**
  - Successful track record and significant pipeline
  - Supportive balance sheet and cash flow
- **Significant potential for adjusted EBITDA margin expansion**
  - Targeting 300-500bps of near and long-term margin expansion driven by:
    - Accretive product mix
    - Pricing / Portfolio
    - G&A leverage
  - Mirion Business System – demonstrated continuous improvement, still early innings

COMPELLING RISK REWARD

Multiple Levers to Create Value

- **Highly predictable and recession resistant platform**
  - Attractive end-market growth
  - Mirion has grown and maintained/expanded margins through recessions and COVID
  - Over 70% of sales are mission critical and recurring
- **Strong acquisition pipeline**
  - Well-honed acquisition playbook
  - Proven track record of value creating M&A
- **Targeting strong free cash flow conversion**
  - Closed transaction provided a de-levered capital structure and balance sheet
  - Further improvement from optimization of working capital and tax reorganization

Recent Events

MIRION TECHNOLOGIES

Mirion completed the business combination on October 20, 2021 with GS Acquisition Holdings Corp II ("GSAH")

Larry Kingsley, former CEO of Pall Corp. and IDEX Corp., named Chairman of the Board.

Reduced pro forma net leverage to ~4.0x after close. Capital structure refinance resulting in reduced interest from L+400 to L+275[1].

Mirion listed on the NYSE under the ticker symbol MIR and bell ringing ceremony on October 21, 2021.

Fiscal year 2021[2] pro forma adjusted revenue of $686M and pro forma adjusted EBITDA of $172.6M.

CIRS

DOSIMETRYBADGE

CHPDOSIMETRY

Completed Medical acquisitions of Dosimetry Badge and CHP.

Signed definitive agreement for CIRS, subject to customary closing conditions.

1) *Legacy Mirion fiscal year, period relating to July 1,2020 to June 30, 2021*
2) *L+275, Libor floor of 50 bps*

Note: For a reconciliation of Adjusted Revenue and Adjusted EBITDA to the most directly comparable GAAP measures, please see Appendix.

Fiscal Quarter Ended September 30, 2021 Summary

Strong execution despite headwinds in supply chain and logistics

Financial performance for quarter ended September 30, 2021 in line with key growth and margin targets

- Adjusted Revenue of $148.0M and Adjusted EBITDA of $30.9M for the quarter
- Organic revenue growth of negative (0.1%) for the quarter vs. prior year period primarily due to higher comp of +8.5% for CYQ3 ’20 over CYQ3 ‘19
- Organic growth of +4.0% for the nine months ended September 2021 vs. same prior year period
- Strong Medical organic growth of +10.8% for the quarter vs. prior year period
- Adjusted gross margins up +310 bps for the quarter vs. prior year period on larger percentage of revenues from Medical segment

Execution of key strategic initiatives in focus

- New product introductions including Lab Pulse and Orion
- Continued integration and footprint consolidation of Nuclear Medicine business, challenged due to supply chain and labor shortages
- Facility consolidations progressing well to deliver incremental gross margin improvement starting in first half of CY22

M&A execution continues, pipeline is robust and healthy

- Signed agreement for acquisition of CIRS, a leader in the RT and Dx phantoms market; bolsters Sun Nuclear portfolio offerings with attractive commercial and cost integration synergies; acquisition subject to customary closing conditions
- Completed Medical Dosimetry acquisitions of Dosimetry Badge and CHP
- Pipeline remains healthy and active, mix slanted towards Medical end-markets

Reiterating 12-months ended June 2022 guidance for Adjusted Revenue and Adjusted EBITDA[1]

1) Guidance excludes approximately $9 million of projected adjusted revenue and $2.5 to $3.0 million of projected adjusted EBITDA from the CIRS acquisition – assuming a Dec. 1, 2021 transaction closing date.
All results shown in this presentation are for Mirion Technologies (TopCo) Ltd ("Legacy Mirion") before the closing of the business combination with GSAH.
Note: For a reconciliation of Adjusted Revenue and Adjusted EBITDA to the most directly comparable GAAP measures, please see Appendix.

Fiscal Quarter Ended September 30, 2021 Performance Summary

Reported adjusted revenues up +29%, prior year organic growth comp of 8.5%

Adjusted Revenue
$ millions

+29%

Organic	*(0.1%)*
Acquisitions	*+28.9%*
FX	*+0.3%*
2Y Organic[1]	*+8.4%*



Adjusted EBITDA
$ millions

+28%



Adjusted Gross Margins

+310 bps

1) 2Y Organic is the combined 2-year sum of CY20 and CY21 organic quarterly growth
References to CYQ3 2021 and 2022 are to the fiscal quarters ended September 30, 2021 and 2022, respectively.
Note: For a reconciliation of Adjusted Revenue and Adjusted EBITDA to the most directly comparable GAAP measures, please see the Appendix.

Fiscal Quarter Ended September 30, 2021 Performance Summary | Medical

Double digit organic growth, acquisitive mix at lower Adjusted EBITDA margins vs. legacy Medical business

Adjusted Revenue

$ millions

+173%

Organic	*+10.8%*
Acquisitions	*+162.3%*
2Y Organic[1]	*+4.8%*



Adjusted EBITDA

$millions

+102%



MEDICAL SEGMENT

Nuclear Medicine
Radiotherapy
Medical Imaging
Occupational Dosimetry

Product Categories

Cancer Diagnostics & Therapeutics QA



Occupational Dosimetry Services

Nuclear Medicine



Medical Imaging

1) 2Y Organic is the combined 2-year sum of CY20 and CY21 organic quarterly growth
References to CYQ3 2021 and 2022 are to the fiscal quarters ended September 30, 2021 and 2022, respectively.
Note: For a reconciliation of Adjusted Revenue and Adjusted EBITDA to the most directly comparable GAAP measures, please see the Appendix.

Fiscal Quarter Ended September 30, 2021 Performance Summary | Industrial

Performance in line with expectations despite comparable growth from prior year (+11.3% organic growth)

Adjusted Revenue
$ millions

(2%)

Organic	*(2.4%)*
FX	*+0.4%*
2Y Organic[1]	*+8.9%*

Adjusted EBITDA
$millions

(5%)



INDUSTRIAL SEGMENT

Nuclear Power
Labs & Research
Diversified Industrial

Product Categories

Laboratory & Scientific Analysis Systems

Radiation Measurement & Health Physics Instrumentation

Search & Radiological Security Systems

Radiation Monitoring Systems



Reactor Instrumentation and Controls

1) 2Y Organic is the combined 2-year sum of CY20 and CY21 organic quarterly growth
References to CYQ3 2021 and 2022 are to the fiscal quarters ended September 30, 2021 and 2022, respectively.
Note: For a reconciliation of Adjusted Revenue and Adjusted EBITDA to the most directly comparable GAAP measures, please see the Appendix.

Post-Close Debt Structure and Liquidity

MIRION TECHNOLOGIES

Debt Structure

- With paydown from SPAC and debt refinancing, reduced annual cash interest from ~$40M+ to less than $27M
  - US dollar term loan margins reduced from L+400 bps to L+275 bps[1]
- Straightforward long-term debt structure following refinancing
  - $830 million term loan maturing 2028
  - $90 million revolver maturing 2026
  - No financial covenants applicable to term loan
- Many lending counterparties previously held Mirion debt. Revolving lenders are well-known commercial banks
- Revolving facility includes springing first lien net leverage covenant set at 7.0x, tested only if revolving loans outstanding (with certain exclusions) exceed 40% of revolving commitments

(Dollars in millions)	**Pro forma Leverage**
Post-close net cash[2]	$ 139
Debt from new first lien term loan	830
LTM June 2021 pro forma adj. EBITDA	$ 173
Total net debt / pro forma adj. EBITDA	**~4.0 x**

Liquidity

- Business combination with GSAH II on October 20th, 2021
- Post-close liquidity of ~$221M, ~$139M of cash[2]
  - Unrestricted cash of ~$138M
  - Undrawn revolver of $90M offset by $8M of LC's
- Post-close pro forma net leverage of ~4.0x after business combination and refinancing
- Adjusted free cash flow better vs. prior year period on improvement in net working capital management and higher adjusted EBITDA

Three months ended (Dollars in millions)	**Sep 30, 2021**	**Sep 30, 2020**
Net cash provided by (used for) operating activities	$ 11.1	$ (6.5)
Purchases of property, plant, and equipment and badges	(8.8)	(5.1)
Free cash flow[3]	**$ 2.3**	**$(11.6)**
Cash used for non-operating expenses	12.9	3.6
Adjusted free cash flow[3]	**$ 15.2**	**$ (8.0)**

Strong liquidity position and post-close capital structure.

1) *L+275, LIBOR floor of 50 bps*
2) *As of October 20, 2021 after giving effect to the close of the business combination with GSAH II*
3) *Adjusted free cash flow is a Non-GAAP metric. Please see the Appendix.*

Guidance for the 12 months ending June 30, 2022[1]

Reiterating guidance for Adjusted revenue and Adjusted EBITDA

	Guidance	Prior Guidance	What we are seeing and expectations
Adjusted Revenue	$723M	$723M	• Strong underlying demand and order book • Supply chain and logistics risks are driving "brush fires"; continue to work through logistics regarding vaccine mandate in the US
Adjusted EBITDA	$179M	$179M	• Incremental public company costs will be a headwind to organic revenue fall-through and EBITDA growth in the short term

Other modelling considerations: Shares[2]: ~189M; USD to EUR FX Rate of 1.23[3]

Guidance excludes approximately $9 million of projected adjusted revenue and $2.5 to $3.0 million of projected adjusted EBITDA from the CIRS acquisition – assuming a December 1, 2021 transaction closing date.

1) Legacy Mirion's last fiscal year ended June 30, 2021 before the business combination with GSAH and guidance was previously given with respect to that fiscal year. Mirion adopted a calendar year fiscal year in connection with the closing of the business combination.
2) Please see Appendix.
3) Guidance and projections assume a Euro to U.S. Dollar exchange rate of 1.23, consistent with the previously provided guidance.
For a reconciliation of Adjusted Revenue to the most directly comparable GAAP measures, please see the Appendix.

Fiscal quarter ended September 30, 2021 Wrap Up

MIRION TECHNOLOGIES

Completion of business combination on October 20, 2021; Mirion Class A common stock listed under ticker NYSE: MIR on October 21, 2021

Fiscal quarter ended September 30, 2021 financial performance in line with expectations

- 2-year organic adjusted revenue growth stack of 8.4% for the quarter ended September 30, 2021
- Adjusted EBITDA for the quarter up +28% compared with the prior-year period
- Adjusted gross margins improving +310 bps on higher Medical segment mix

Reiterate 12-months ended June, 30 2022 guidance for Adjusted Revenue and Adjusted EBITDA[1]

- Industrial focus on new product launches (Orion, Lab Pulse, Accurad and Aegis) while managing through supply chain disruptions
- Medical executing on acquisition business integration and new product launches

Executing on M&A campaign with three medical acquisitions, pipeline is healthy and robust

- CIRS leading position in phantoms complimenting Sun Nuclear portfolio (pending close and customary closing conditions)
- Continued consolidation of Dosimetry opportunities with Dosimetry Badge and CHP

1) Guidance excludes $9 million of projected adjusted revenue and $2.5 to $3.0 million of projected adjusted EBITDA from the CIRS acquisition – assuming a Dec. 1, 2021 transaction closing date.
Note: For a reconciliation of Adjusted Revenue and Adjusted EBITDA to the most directly comparable GAAP measures, please see the Appendix.

Appendix

Mirion to Acquire CIRS

Continued expansion into Medical leveraging Sun Nuclear platform

- Mirion has entered into a definitive agreement to acquire Computerized Imaging Reference Systems, Inc. (“CIRS”); the acquisition is subject to customary closing conditions and is expected to close in the fourth calendar quarter of 2021
- CIRS offers radiotherapy (“RT”) and radio-diagnostic (“Dx”) phantoms globally; CIRS and Mirion / Sun Nuclear businesses are highly complementary
- The acquisition of CIRS is expected to support Mirion’s expansion into the medical market, building upon the Sun Nuclear platform in an accretive fashion
    - The transaction is expected to improve our share position in the phantom segment
    - Cost and commercial synergies will be accretive to Medical segment margins over time

Company Overview:

- CIRS specializes in the design, development & commercialization of tissue equivalent medical imaging & radiation therapy phantoms ("phantoms") for the RT and Dx markets
- Its technology is used to:
    - calibrate & routinely test diagnostic imaging & radiation therapy equipment;
    - measure radiation dose in specific anatomical geometries;
    - maintain critical quality assurance standards, & most importantly;
    - improve patient outcomes
- CIRS serves a diverse customer base including medical imaging and radiation therapy OEMs, clinicians, and research institutions

CIRS

- Purchase Price $54M
- CY 2022 Estimates[1, 3, 4]
    - Adjusted Revenue ~$16M
    - Adjusted EBITDA[2] ~$5M
- Headquarters: Norfolk, Virginia
- ~80 Employees



1) *Estimates provided by CIRS and cannot be confirmed by Mirion or its auditors*
2) *Adjusted EBITDA excludes synergies*
3) *Adjusted Revenue is defined as U.S. GAAP revenue adjusted to remove the impact of purchase accounting on the recognition of deferred revenue.*
4) *Adjusted EBITDA is defined as net income before interest expense, income tax expense, depreciation and amortization adjusted to remove the effect of stock compensation expense, debt extinguishment, foreign currency, purchase accounting on the recognition of deferred revenue, the cost of revenues impact from inventory valuation purchase accounting and certain other non- operating expenses.*

Backlog Trend | Q3 CY19 to Q3 CY21

$ millions



Note: Backlog figures on an As Reported basis
Backlog figures include acquisitions of Capintec after Jul-19, Premium Analyse after Sep-19, Selmic after Oct-19, Biodex after Oct-20 and Sun Nuclear after Dec-20

Non-GAAP Reconciliations

Adjusted Revenue, Income from Operations, Gross Profit & Adjusted EBITDA

MIRION TECHNOLOGIES

For the three months ended September 30th, 2021 & 2020
$ in millions

Reconciliation of Net Loss to Income from Operations

	Sep-21	Sep-20
Net loss	$ (46.7)	$ (40.4)
Interest expense, net	43.8	37.9
Income tax (benefit) provision	(4.7)	(1.0)
Foreign currency (gain) loss, net	(1.4)	8.1
Other income (expense)	0.1	-
Income from Operations	**$ (8.9)**	**$ 4.6**

Reconciliation of Income from Operations to Adjusted EBITDA

	Sep-21	Sep-20
Medical	$ 2.6	$ 4.0
Industrial	12.5	11.4
Corporate and Other	(24.0)	(10.8)
Income from Operations	**$ (8.9)**	**$ 4.6**
Amortization	$ 16.1	$ 12.2
Depreciation	5.1	4.3
Revenue adj. from purchase accounting	3.7	-
Non-Operating expenses	14.9	2.9
Adjusted EBITDA	**$ 30.9**	**$ 24.0**

Reconciliation of Gross Profit

	Sep-21	Sep-20
Gross Profit	$ 61.9	$ 46.7
Amortization	3.5	3.2
Depreciation	5.4	4.6
Revenue adj. from purchase accounting	3.7	-
Non-Operating expenses	1.0	0.4
Adjusted Gross Profit	**$ 75.5**	**$ 54.9**
Adjusted gross margin as % of revenue[2]	51.0%	47.9%

For the three months ended September 30th, 2021 & 2020
$ in millions

Segmented Reconciliation of Adjusted Revenue & EBITDA

	Sep-21			
	Medical	Industrial	Corp & Other	Consolidated
Revenue (GAAP, as reported)	$ 52.0	$ 92.3	$ -	$ 144.3
Deferred revenue purchase accounting adj.	3.7	-	-	3.7
Adjusted Revenue	**$ 55.7**	**$ 92.3**	**$ -**	**$ 148.0**
Income from operations	$ 2.6	$ 12.5	$ (24.0)	$ (8.9)
Amortization	8.0	8.1	-	16.1
Depreciation	2.8	2.1	0.2	5.1
Revenue reduction from purchase acct.	3.7	-	-	3.7
Non-Operating expenses	-	-	14.9	14.9
Adjusted EBITDA	**$ 17.1**	**$ 22.7**	**$ (8.9)**	**$ 30.9**
Income from operations as % of revenue[1]	5.0%	13.5%	n.a	**-6.2%**
Adjusted EBITDA as % of revenue[2]	30.7%	24.6%	n.a	**20.9%**

	Sep-20			
	Medical	Industrial	Corp & Other	Consolidated
Revenue (GAAP, as reported)	$ 20.4	$ 94.2	$ -	$ 114.6
Deferred revenue purchase accounting adj.	-	-	-	-
Adjusted Revenue	**$ 20.4**	**$ 94.2**	**$ -**	**$ 114.6**
Income from operations	$ 4.0	$ 11.4	$ (10.8)	$ 4.6
Amortization	2.4	9.8	-	12.2
Depreciation	1.9	2.4	-	4.3
Non-Operating expenses	-	-	2.9	2.9
Adjusted EBITDA	**$ 8.3**	**$ 23.6**	**$ (7.9)**	**$ 24.0**
Income from operations as % of revenue[1]	19.6%	12.1%	n.a	**4.0%**
Adjusted EBITDA as % of revenue[2]	40.7%	25.1%	n.a	**20.9%**

1) *Calculation based on Revenue (GAAP, as reported)*
2) *Calculation based on Adjusted Revenue*

Non-GAAP Reconciliations

Adjusted Revenue Growth & Pro forma Revenue and EBITDA

For the twelve months ended June 30th, 2021
$ in millions

Reconciliation of Pro forma Adjusted Revenue & EBITDA

		Jun-21
Revenue (GAAP, as reported)	$	611.6
Deferred revenue purchase accounting adj.		8.0
Adjusted Revenue	**$**	**619.6**
Pro forma adjustments from acquisitions		60.0
FX impact		6.3
Pro forma Adjusted Revenue	**$**	**685.9**

		Jun-21
Net income (GAAP, as reported)	$	(158.3)
Minority interest		(0.1)
Income taxes		(5.9)
Other (income) / expense		(1.1)
Loss on debt extinguishment		-
FX (gain) / loss		13.4
Net interest expense		163.2
Amortization of acquired intangibles		62.9
Depreciation		20.8
Stock based compensation		-
Other non-operating costs		49.0
Deferred revenue purchase accounting adj.		8.0
Other adjustments		0.4
Adjusted EBITDA	**$**	**152.2**
Pro forma adjustments from acquisitions		19.2
FX impact		1.2
Pro forma Adjusted EBITDA	**$**	**172.6**

For the three months ended September 30th, 2021, 2020 & 2019
$ in millions

					Δ%			
		Sep-21		Sep-20	Total	Organic	Acquisitions	FX
Medical	$	55.7	$	20.4	173.0%	10.8%	162.3%	0.0%
Industrial		92.3		94.2	-2.0%	-2.4%	0.0%	0.4%
Total Adjusted Revenue	**$**	**148.0**	**$**	**114.6**	**29.1%**	**-0.1%**	**28.9%**	**0.3%**
Deferred revenue purchase accounting adj.		(3.7)		-				
Revenue (GAAP, as reported)	**$**	**144.3**	**$**	**114.6**				

					Δ%			
		Sep-20		Sep-19	Total	Organic	Acquisitions	FX
Medical	$	20.4	$	15.1	35.2%	-6.0%	39.8%	1.3%
Industrial		94.2		80.0	17.8%	11.3%	3.6%	2.9%
Total Adjusted Revenue	**$**	**114.6**	**$**	**95.1**	**20.5%**	**8.5%**	**9.4%**	**2.6%**
Deferred revenue purchase accounting adj.		-		-				
Revenue (GAAP, as reported)	**$**	**114.6**	**$**	**95.1**				

For the nine months ended September 30th, 2021, 2020 & 2019
$ in millions

					Δ%			
		Sep-21		Sep-20	Total	Organic	Acquisitions	FX
Medical	$	167.3	$	53.8	211.0%	5.0%	204.3%	1.6%
Industrial		334.9		312.0	7.3%	3.9%	0.0%	3.5%
Total Adjusted Revenue	**$**	**502.2**	**$**	**365.8**	**37.3%**	**4.0%**	**30.1%**	**3.2%**
Deferred revenue purchase accounting adj.		(11.7)		(0.2)				
Revenue (GAAP, as reported)	**$**	**490.5**	**$**	**365.6**				

					Δ%			
		Sep-20		Sep-19	Total	Organic	Acquisitions	FX
Medical	$	53.8	$	37.6	43.0%	1.1%	41.7%	0.2%
Industrial		312.0		291.4	7.1%	3.6%	3.4%	0.0%
Total Adjusted Revenue	**$**	**365.8**	**$**	**329.0**	**11.2%**	**3.3%**	**7.8%**	**0.0%**
Deferred revenue purchase accounting adj.		(0.2)		-				
Revenue (GAAP, as reported)	**$**	**365.6**	**$**	**329.0**				

Footnote to Adjusted Free Cash Flow and Share Count

Adjusted Free Cash Flow

Free cash flow and Adjusted free cash flow are supplemental measures of our performance that are not required by, or presented in accordance with, U.S. GAAP. We believe that free cash flow and Adjusted free cash flow are important because they provide management with measurements of cash generated from operations that is available for payment obligations and investment opportunities, such as repaying debt and funding acquisitions.

Free cash flow is defined as U.S. GAAP net cash provided by operating activities adjusted to include the impact of purchases of property, plant, and equipment and purchases of badges. Adjusted free cash flow is defined as free cash flow adjusted to include the impact of cash used to fund non-operating expenses (as previously defined). We believe that the inclusion of supplementary adjustments to free cash flow applied in presenting Adjusted free cash flow is appropriate to provide additional information to investors about our cash flows that management utilizes on an ongoing basis to assess our ability to generate cash for use in acquisitions and other investing and financing activities.

Free cash flow and Adjusted free cash flow may not be comparable to similarly titled measures used by other companies. You should not consider our Free cash flow or Adjusted free cash flow as alternatives to net cash provided by (used for) operating activities in accordance with U.S. GAAP.

Share Count

Consists of 180,773,292 shares of Class A common stock and 8,560,540 shares of Class B common stock outstanding as of October 20, 2021. Excludes (1) 18,750,000 shares of Class A common stock subject to vesting in three equal tranches, based on the volume-weighted average price of our Class A common stock being greater than or equal to $12.00, $14.00 and $16.00 per share for any 20 trading days in any 30 consecutive trading day period, and such shares will be forfeited to us if they fail to vest within five years after October 20, 2021; (2) 27,249,979 shares of Class A common stock issuable upon the exercise of 8,500,000 private placement warrants and 18,749,979 publicly-traded warrants; and (3) any shares issuable from awards under our 2021 Omnibus Incentive Plan. The 8,560,540 shares of Class B common stock are exchangeable for up to 8,560,540 shares of Class A common stock on a one-for-one basis.

MIRION
TECHNOLOGIES

MIR
LISTED
NYSE